This is a single site, randomized, double-blind, placebo-controlled, within-subjects study design in healthy volunteers. Escalating single doses of ITI-214 will be evaluated using functional magnetic resonance imaging (fMRI) to determine central nervous system engagement. Safety and tolerability also will be assessed.

Inclusion Criteria:

• Healthy male or female, 18 - 45 years
• Fluent and literate in English and able to provide written informed consent
• BMI between 18.5 and 38.0 kg/m2 and minimum body weight of 50 kg

Exclusion Criteria:

• Recent exposure to any investigational product
• Previous exposure to relevant fMRI task(s)
• Considered medically unsuitable for participation
• Has any contraindication for BOLD fMRI